chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Ageusia, Angiogram, Arthralgia, Back pain, Bell's palsy
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Blood iron normal, Blood thyroid stimulating hormone normal, C-reactive protein normal, CSF protein increased, CSF white blood cell count increased
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Computerised tomogram spine, Cytology, Electromyogram, Eye movement disorder, Facial paresis
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Flow cytometry, Full blood count normal, Guillain-Barre syndrome, Headache, Hypoaesthesia
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Immunoglobulin therapy, Lagophthalmos, Lumbar puncture abnormal, Magnetic resonance imaging abnormal, Metabolic function test normal
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Muscle spasms, Neurological examination abnormal, Pain, Pain in extremity, Prostatic specific antigen normal
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Red blood cell sedimentation rate normal, Spinal osteoarthritis, Tenderness, Treponema test negative, Vertebral foraminal stenosis
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Arthralgia, Back pain, Bell's palsy, Blood iron normal, Blood thyroid stimulating hormone normal
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: C-reactive protein normal, CSF protein increased, CSF white blood cell count increased, Computerised tomogram abdomen normal, Computerised tomogram head normal
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Computerised tomogram spine, Computerised tomogram thorax normal, Cytology normal, Electromyogram abnormal, Facial pain
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Facial paresis, Flow cytometry, Full blood count normal, Guillain-Barre syndrome, Headache
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Hypoaesthesia, Immunoglobulin therapy, Intervertebral disc space narrowing, Lumbar puncture abnormal, Magnetic resonance imaging head abnormal
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Magnetic resonance imaging spinal abnormal, Metabolic function test normal, Muscle spasms, Neurological examination abnormal, Pain
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Prostatic specific antigen normal, Red blood cell sedimentation rate normal, Spinal osteoarthritis, Tenderness, Treponema test negative
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Vitamin B12 normal
Clinical narrative: The Jansen vaccine was given on 3/18/21. Patient began to experience symptoms of bells palsy on 4/6/21. Patient noted  R hemibody numbness, which began with right-sided facial numbness when brushing teeth. He was evaluated by his PCP (no exam noted) and initiated on Bells Palsy regimen of doxycycline 100mg BID, acyclovir 800mg TID, and prednisone 40mg. On 4/9, a referral to neurology was made after pt returned to clinic w/ burning deep low back pain that radiates up to his shoulder, and his b/l temples. Pt again re-presented to urgent care on 4/12 due to severe burning back pain that resolved w/ activity. At this time again only L sided facial weakness noted (documented as reduced ability to close eyelid, raise eyebrow, weakness puffing out check, and reduced smile on L), no other weakness, drift, or sensory findings. Pt was instructed to continue doxycylilne 100mg BID 10d course (4/6- 4/15), prednisone 40mg 7d course (4/6- 4/12), acyclovir 800mg TID 7d course(4/6-4/12).
Age: 16.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Headache, Product administered to patient of inappropriate age, Pyrexia
Clinical narrative: PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE; OFF LABEL USE; FEVER; DIFFICULTY PERFORMING EVERYDAY  ACTIVITY; GENERAL SENSE OF CONFUSION; EXCRUCIATING HEADACHE; This spontaneous report received from a parent concerned a 16 year old male. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 203A21A expiry: UNKNOWN) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 10-APR-2021, the subject experienced general sense of confusion. On 10-APR-2021, the subject experienced excruciating headache. On 11-APR-2021, the subject experienced difficulty performing everyday activity. On an unspecified date, the subject experienced product administered to subject of inappropriate age, off label use, and fever. Laboratory data (dates unspecified) included: Body temperature (NR: not provided) 103 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from general sense of confusion on 11-APR-2021, and the outcome of difficulty performing everyday activity, fever, excruciating headache, product administered to patient of inappropriate age and off label use was not reported. This report was non-serious.
Age: 16.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Chills, Disorientation, Dizziness, Headache, Pyrexia
Clinical narrative: PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE; OFF LABEL USE; FEVER; DIFFICULTY PERFORMING EVERYDAY  ACTIVITY; GENERAL SENSE OF CONFUSION; EXCRUCIATING HEADACHE; This spontaneous report received from a parent concerned a 16 year old male. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 203A21A expiry: UNKNOWN) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 10-APR-2021, the subject experienced general sense of confusion. On 10-APR-2021, the subject experienced excruciating headache. On 11-APR-2021, the subject experienced difficulty performing everyday activity. On an unspecified date, the subject experienced product administered to subject of inappropriate age, off label use, and fever. Laboratory data (dates unspecified) included: Body temperature (NR: not provided) 103 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from general sense of confusion on 11-APR-2021, and the outcome of difficulty performing everyday activity, fever, excruciating headache, product administered to patient of inappropriate age and off label use was not reported. This report was non-serious.
Age: 16.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Body temperature, Confusional state, Headache, Loss of personal independence in daily activities, Off label use
Clinical narrative: PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE; OFF LABEL USE; FEVER; DIFFICULTY PERFORMING EVERYDAY  ACTIVITY; GENERAL SENSE OF CONFUSION; EXCRUCIATING HEADACHE; This spontaneous report received from a parent concerned a 16 year old male. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 203A21A expiry: UNKNOWN) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 10-APR-2021, the subject experienced general sense of confusion. On 10-APR-2021, the subject experienced excruciating headache. On 11-APR-2021, the subject experienced difficulty performing everyday activity. On an unspecified date, the subject experienced product administered to subject of inappropriate age, off label use, and fever. Laboratory data (dates unspecified) included: Body temperature (NR: not provided) 103 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from general sense of confusion on 11-APR-2021, and the outcome of difficulty performing everyday activity, fever, excruciating headache, product administered to patient of inappropriate age and off label use was not reported. This report was non-serious.
Age: 16.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Product administered to patient of inappropriate age, Pyrexia
Clinical narrative: PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE; OFF LABEL USE; FEVER; DIFFICULTY PERFORMING EVERYDAY  ACTIVITY; GENERAL SENSE OF CONFUSION; EXCRUCIATING HEADACHE; This spontaneous report received from a parent concerned a 16 year old male. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 203A21A expiry: UNKNOWN) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 10-APR-2021, the subject experienced general sense of confusion. On 10-APR-2021, the subject experienced excruciating headache. On 11-APR-2021, the subject experienced difficulty performing everyday activity. On an unspecified date, the subject experienced product administered to subject of inappropriate age, off label use, and fever. Laboratory data (dates unspecified) included: Body temperature (NR: not provided) 103 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from general sense of confusion on 11-APR-2021, and the outcome of difficulty performing everyday activity, fever, excruciating headache, product administered to patient of inappropriate age and off label use was not reported. This report was non-serious.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Headache, Pain, Pyrexia, SARS-CoV-2 test negative
Clinical narrative: EYES WATERY; BODY ACHES; FEVER/CHILLS; This spontaneous report received from a patient concerned a 39 year old male. The patient's weight, height, and medical history were not reported.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 041A21A,  expiry: UNKNOWN) dose was not reported, administered on 02-APR-2021 21:00 for prophylactic vaccination. No concomitant medications were reported.  On APR-2021, Laboratory data included: COVID-19 PCR test (NR: not provided) Pending at this time (units unspecified), and COVID-19 antigen test (NR: not provided) Negative (units unspecified). On 02-APR-2021, the subject experienced eyes watery. On 02-APR-2021, the subject experienced body aches. On 02-APR-2021, the subject experienced fever/chills. Laboratory data included: Body temperature (NR: not provided) 99.5 F. On 03-APR-2021, Laboratory data included: Body temperature (NR: not provided) 100.4 F. On 12-APR-2021, Laboratory data included: Body temperature (NR: not provided) 99.4 F. Treatment medications (dates unspecified) included: ibuprofen. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from body aches on 05-APR-2021, and had not recovered from fever/chills, and eyes watery. This report was non-serious.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Body temperature, Lacrimation increased, Pain, Pyrexia, SARS-CoV-2 test
Clinical narrative: EYES WATERY; BODY ACHES; FEVER/CHILLS; This spontaneous report received from a patient concerned a 39 year old male. The patient's weight, height, and medical history were not reported.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 041A21A,  expiry: UNKNOWN) dose was not reported, administered on 02-APR-2021 21:00 for prophylactic vaccination. No concomitant medications were reported.  On APR-2021, Laboratory data included: COVID-19 PCR test (NR: not provided) Pending at this time (units unspecified), and COVID-19 antigen test (NR: not provided) Negative (units unspecified). On 02-APR-2021, the subject experienced eyes watery. On 02-APR-2021, the subject experienced body aches. On 02-APR-2021, the subject experienced fever/chills. Laboratory data included: Body temperature (NR: not provided) 99.5 F. On 03-APR-2021, Laboratory data included: Body temperature (NR: not provided) 100.4 F. On 12-APR-2021, Laboratory data included: Body temperature (NR: not provided) 99.4 F. Treatment medications (dates unspecified) included: ibuprofen. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from body aches on 05-APR-2021, and had not recovered from fever/chills, and eyes watery. This report was non-serious.
Age: 23.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Dizziness, Visual impairment
Clinical narrative: dizziness , loss of vision for 5 minutes after shot  urgent care
Age: 23.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Asthenia, Blindness, Blood pressure increased, Blood pressure measurement, Body temperature
Clinical narrative: dizziness , loss of vision for 5 minutes after shot  urgent care
Age: 23.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Body temperature decreased, Cardiovascular disorder, Chest discomfort, Cyanosis, Dysphagia
Clinical narrative: dizziness , loss of vision for 5 minutes after shot  urgent care
Age: 23.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Heart rate, Hyperhidrosis, Intracranial pressure increased, Mydriasis, Pulmonary function test
Clinical narrative: dizziness , loss of vision for 5 minutes after shot  urgent care
Age: 23.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Sinus rhythm
Clinical narrative: dizziness , loss of vision for 5 minutes after shot  urgent care
Age: 23.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blindness, Dizziness
Clinical narrative: dizziness , loss of vision for 5 minutes after shot  urgent care
Age: 45.0
Sex: U
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Brain death, Cerebral venous sinus thrombosis, Death, Dizziness, Headache
Clinical narrative: 3/21/21 Headache reported. 3/22/21 Awakened at home with headache. 3/23/21 PCP ordered CT of Head - normal. 3/24/21 PCP repeated CT of head - mucosal thickening of right sinus. 3/24/21 - Arrive to ED with intractable headache and nausea. 3/25/21 CT of head right parietal intraparenchymal hematoma 5 cc.  Mannitol infused. Loss of pupil reflexes noted. Right decompressive craniectomy by Dr.  Following surgery ICP was >60. Remained intubated. 3/26/21 - ICP remains high. No reflexes noted. 3/27/21 - brain death confirmed by Dr.
Age: 45.0
Sex: U
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Vomiting
Clinical narrative: 3/21/21 Headache reported. 3/22/21 Awakened at home with headache. 3/23/21 PCP ordered CT of Head - normal. 3/24/21 PCP repeated CT of head - mucosal thickening of right sinus. 3/24/21 - Arrive to ED with intractable headache and nausea. 3/25/21 CT of head right parietal intraparenchymal hematoma 5 cc.  Mannitol infused. Loss of pupil reflexes noted. Right decompressive craniectomy by Dr.  Following surgery ICP was >60. Remained intubated. 3/26/21 - ICP remains high. No reflexes noted. 3/27/21 - brain death confirmed by Dr.
Age: 45.0
Sex: U
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Cerebral venous sinus thrombosis, Dizziness, Headache, Vomiting
Clinical narrative: 3/21/21 Headache reported. 3/22/21 Awakened at home with headache. 3/23/21 PCP ordered CT of Head - normal. 3/24/21 PCP repeated CT of head - mucosal thickening of right sinus. 3/24/21 - Arrive to ED with intractable headache and nausea. 3/25/21 CT of head right parietal intraparenchymal hematoma 5 cc.  Mannitol infused. Loss of pupil reflexes noted. Right decompressive craniectomy by Dr.  Following surgery ICP was >60. Remained intubated. 3/26/21 - ICP remains high. No reflexes noted. 3/27/21 - brain death confirmed by Dr.
Age: 45.0
Sex: U
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Blood fibrinogen decreased, Brain death, Cerebral haematoma, Computerised tomogram head abnormal, Decompressive craniectomy
Clinical narrative: 3/21/21 Headache reported. 3/22/21 Awakened at home with headache. 3/23/21 PCP ordered CT of Head - normal. 3/24/21 PCP repeated CT of head - mucosal thickening of right sinus. 3/24/21 - Arrive to ED with intractable headache and nausea. 3/25/21 CT of head right parietal intraparenchymal hematoma 5 cc.  Mannitol infused. Loss of pupil reflexes noted. Right decompressive craniectomy by Dr.  Following surgery ICP was >60. Remained intubated. 3/26/21 - ICP remains high. No reflexes noted. 3/27/21 - brain death confirmed by Dr.
Age: 45.0
Sex: U
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Endotracheal intubation, Headache, Influenza A virus test negative, Influenza B virus test, Influenza virus test negative
Clinical narrative: 3/21/21 Headache reported. 3/22/21 Awakened at home with headache. 3/23/21 PCP ordered CT of Head - normal. 3/24/21 PCP repeated CT of head - mucosal thickening of right sinus. 3/24/21 - Arrive to ED with intractable headache and nausea. 3/25/21 CT of head right parietal intraparenchymal hematoma 5 cc.  Mannitol infused. Loss of pupil reflexes noted. Right decompressive craniectomy by Dr.  Following surgery ICP was >60. Remained intubated. 3/26/21 - ICP remains high. No reflexes noted. 3/27/21 - brain death confirmed by Dr.
Age: 45.0
Sex: U
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Intracranial pressure increased, Mucosal hypertrophy, Nausea, Platelet count decreased, Pupillary reflex impaired
Clinical narrative: 3/21/21 Headache reported. 3/22/21 Awakened at home with headache. 3/23/21 PCP ordered CT of Head - normal. 3/24/21 PCP repeated CT of head - mucosal thickening of right sinus. 3/24/21 - Arrive to ED with intractable headache and nausea. 3/25/21 CT of head right parietal intraparenchymal hematoma 5 cc.  Mannitol infused. Loss of pupil reflexes noted. Right decompressive craniectomy by Dr.  Following surgery ICP was >60. Remained intubated. 3/26/21 - ICP remains high. No reflexes noted. 3/27/21 - brain death confirmed by Dr.
Age: 45.0
Sex: U
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Respiratory syncytial virus test negative, SARS-CoV-2 test negative, White blood cell count increased
Clinical narrative: 3/21/21 Headache reported. 3/22/21 Awakened at home with headache. 3/23/21 PCP ordered CT of Head - normal. 3/24/21 PCP repeated CT of head - mucosal thickening of right sinus. 3/24/21 - Arrive to ED with intractable headache and nausea. 3/25/21 CT of head right parietal intraparenchymal hematoma 5 cc.  Mannitol infused. Loss of pupil reflexes noted. Right decompressive craniectomy by Dr.  Following surgery ICP was >60. Remained intubated. 3/26/21 - ICP remains high. No reflexes noted. 3/27/21 - brain death confirmed by Dr.
Age: 45.0
Sex: U
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Blood fibrinogen, Brain death, CSF pressure, Cerebral haematoma, Computerised tomogram
Clinical narrative: 3/21/21 Headache reported. 3/22/21 Awakened at home with headache. 3/23/21 PCP ordered CT of Head - normal. 3/24/21 PCP repeated CT of head - mucosal thickening of right sinus. 3/24/21 - Arrive to ED with intractable headache and nausea. 3/25/21 CT of head right parietal intraparenchymal hematoma 5 cc.  Mannitol infused. Loss of pupil reflexes noted. Right decompressive craniectomy by Dr.  Following surgery ICP was >60. Remained intubated. 3/26/21 - ICP remains high. No reflexes noted. 3/27/21 - brain death confirmed by Dr.
Age: 45.0
Sex: U
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Computerised tomogram head, Headache, Influenza, Intracranial pressure increased, Platelet disorder
Clinical narrative: 3/21/21 Headache reported. 3/22/21 Awakened at home with headache. 3/23/21 PCP ordered CT of Head - normal. 3/24/21 PCP repeated CT of head - mucosal thickening of right sinus. 3/24/21 - Arrive to ED with intractable headache and nausea. 3/25/21 CT of head right parietal intraparenchymal hematoma 5 cc.  Mannitol infused. Loss of pupil reflexes noted. Right decompressive craniectomy by Dr.  Following surgery ICP was >60. Remained intubated. 3/26/21 - ICP remains high. No reflexes noted. 3/27/21 - brain death confirmed by Dr.
Age: 45.0
Sex: U
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: SARS-CoV-2 test, Sinus disorder, White blood cell count
Clinical narrative: 3/21/21 Headache reported. 3/22/21 Awakened at home with headache. 3/23/21 PCP ordered CT of Head - normal. 3/24/21 PCP repeated CT of head - mucosal thickening of right sinus. 3/24/21 - Arrive to ED with intractable headache and nausea. 3/25/21 CT of head right parietal intraparenchymal hematoma 5 cc.  Mannitol infused. Loss of pupil reflexes noted. Right decompressive craniectomy by Dr.  Following surgery ICP was >60. Remained intubated. 3/26/21 - ICP remains high. No reflexes noted. 3/27/21 - brain death confirmed by Dr.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Back pain, Chills, Decreased appetite, Diarrhoea, Fatigue
Clinical narrative: DIARRHEA; VOMITING; GASTRO-INTESTINAL SYMPTOMS; FATIGUE; HEADACHE; NAUSEA; MUSCLE ACHES; BODY PAIN; PAIN AT INJECTION SITE; BODY TEMPERATURE INCREASED; FEVER; NIGHT SWEATS; CHILLS; This spontaneous report received from a patient concerned a 56 year old female. The patient's weight was 176 pounds, and height was 63 inches. The patient's past medical history included covid-19 infection, low thyroid, and kidney disease, and concurrent conditions included bactrim allergy. The patient experienced drug allergy when treated with morphine, and hydrocodone bitartrate/paracetamol. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 10-APR-2021, the subject experienced body pain. On 10-APR-2021, the subject experienced night sweats. On 10-APR-2021, the subject experienced chills. On 10-APR-2021, the subject experienced muscle aches. On 10-APR-2021, the subject experienced pain at injection site. On 10-APR-2021, the subject experienced body temperature increased. On 10-APR-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 99.1 F. On 11-APR-2021, the subject experienced diarrhea. On 11-APR-2021, the subject experienced vomiting. On 11-APR-2021, the subject experienced gastro-intestinal symptoms. On 11-APR-2021, the subject experienced headache. On 11-APR-2021, the subject experienced nausea. On 11-APR-2021, the subject experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from diarrhea, night sweats, chills, nausea, and fever on APR-2021, and vomiting on 11-APR-2021, was recovering from headache, muscle aches, fatigue, pain at injection site, and body pain, and the outcome of body temperature increased and gastro-intestinal symptoms was not reported. This report was non-serious.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Headache, Injection site pain, Injection site warmth, Muscle fatigue, Nausea
Clinical narrative: DIARRHEA; VOMITING; GASTRO-INTESTINAL SYMPTOMS; FATIGUE; HEADACHE; NAUSEA; MUSCLE ACHES; BODY PAIN; PAIN AT INJECTION SITE; BODY TEMPERATURE INCREASED; FEVER; NIGHT SWEATS; CHILLS; This spontaneous report received from a patient concerned a 56 year old female. The patient's weight was 176 pounds, and height was 63 inches. The patient's past medical history included covid-19 infection, low thyroid, and kidney disease, and concurrent conditions included bactrim allergy. The patient experienced drug allergy when treated with morphine, and hydrocodone bitartrate/paracetamol. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 10-APR-2021, the subject experienced body pain. On 10-APR-2021, the subject experienced night sweats. On 10-APR-2021, the subject experienced chills. On 10-APR-2021, the subject experienced muscle aches. On 10-APR-2021, the subject experienced pain at injection site. On 10-APR-2021, the subject experienced body temperature increased. On 10-APR-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 99.1 F. On 11-APR-2021, the subject experienced diarrhea. On 11-APR-2021, the subject experienced vomiting. On 11-APR-2021, the subject experienced gastro-intestinal symptoms. On 11-APR-2021, the subject experienced headache. On 11-APR-2021, the subject experienced nausea. On 11-APR-2021, the subject experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from diarrhea, night sweats, chills, nausea, and fever on APR-2021, and vomiting on 11-APR-2021, was recovering from headache, muscle aches, fatigue, pain at injection site, and body pain, and the outcome of body temperature increased and gastro-intestinal symptoms was not reported. This report was non-serious.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Night sweats, Pyrexia
Clinical narrative: DIARRHEA; VOMITING; GASTRO-INTESTINAL SYMPTOMS; FATIGUE; HEADACHE; NAUSEA; MUSCLE ACHES; BODY PAIN; PAIN AT INJECTION SITE; BODY TEMPERATURE INCREASED; FEVER; NIGHT SWEATS; CHILLS; This spontaneous report received from a patient concerned a 56 year old female. The patient's weight was 176 pounds, and height was 63 inches. The patient's past medical history included covid-19 infection, low thyroid, and kidney disease, and concurrent conditions included bactrim allergy. The patient experienced drug allergy when treated with morphine, and hydrocodone bitartrate/paracetamol. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 10-APR-2021, the subject experienced body pain. On 10-APR-2021, the subject experienced night sweats. On 10-APR-2021, the subject experienced chills. On 10-APR-2021, the subject experienced muscle aches. On 10-APR-2021, the subject experienced pain at injection site. On 10-APR-2021, the subject experienced body temperature increased. On 10-APR-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 99.1 F. On 11-APR-2021, the subject experienced diarrhea. On 11-APR-2021, the subject experienced vomiting. On 11-APR-2021, the subject experienced gastro-intestinal symptoms. On 11-APR-2021, the subject experienced headache. On 11-APR-2021, the subject experienced nausea. On 11-APR-2021, the subject experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from diarrhea, night sweats, chills, nausea, and fever on APR-2021, and vomiting on 11-APR-2021, was recovering from headache, muscle aches, fatigue, pain at injection site, and body pain, and the outcome of body temperature increased and gastro-intestinal symptoms was not reported. This report was non-serious.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Body temperature, Body temperature increased, Chills, Diarrhoea, Fatigue
Clinical narrative: DIARRHEA; VOMITING; GASTRO-INTESTINAL SYMPTOMS; FATIGUE; HEADACHE; NAUSEA; MUSCLE ACHES; BODY PAIN; PAIN AT INJECTION SITE; BODY TEMPERATURE INCREASED; FEVER; NIGHT SWEATS; CHILLS; This spontaneous report received from a patient concerned a 56 year old female. The patient's weight was 176 pounds, and height was 63 inches. The patient's past medical history included covid-19 infection, low thyroid, and kidney disease, and concurrent conditions included bactrim allergy. The patient experienced drug allergy when treated with morphine, and hydrocodone bitartrate/paracetamol. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 10-APR-2021, the subject experienced body pain. On 10-APR-2021, the subject experienced night sweats. On 10-APR-2021, the subject experienced chills. On 10-APR-2021, the subject experienced muscle aches. On 10-APR-2021, the subject experienced pain at injection site. On 10-APR-2021, the subject experienced body temperature increased. On 10-APR-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 99.1 F. On 11-APR-2021, the subject experienced diarrhea. On 11-APR-2021, the subject experienced vomiting. On 11-APR-2021, the subject experienced gastro-intestinal symptoms. On 11-APR-2021, the subject experienced headache. On 11-APR-2021, the subject experienced nausea. On 11-APR-2021, the subject experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from diarrhea, night sweats, chills, nausea, and fever on APR-2021, and vomiting on 11-APR-2021, was recovering from headache, muscle aches, fatigue, pain at injection site, and body pain, and the outcome of body temperature increased and gastro-intestinal symptoms was not reported. This report was non-serious.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Gastrointestinal disorder, Headache, Injection site pain, Myalgia, Nausea
Clinical narrative: DIARRHEA; VOMITING; GASTRO-INTESTINAL SYMPTOMS; FATIGUE; HEADACHE; NAUSEA; MUSCLE ACHES; BODY PAIN; PAIN AT INJECTION SITE; BODY TEMPERATURE INCREASED; FEVER; NIGHT SWEATS; CHILLS; This spontaneous report received from a patient concerned a 56 year old female. The patient's weight was 176 pounds, and height was 63 inches. The patient's past medical history included covid-19 infection, low thyroid, and kidney disease, and concurrent conditions included bactrim allergy. The patient experienced drug allergy when treated with morphine, and hydrocodone bitartrate/paracetamol. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 10-APR-2021, the subject experienced body pain. On 10-APR-2021, the subject experienced night sweats. On 10-APR-2021, the subject experienced chills. On 10-APR-2021, the subject experienced muscle aches. On 10-APR-2021, the subject experienced pain at injection site. On 10-APR-2021, the subject experienced body temperature increased. On 10-APR-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 99.1 F. On 11-APR-2021, the subject experienced diarrhea. On 11-APR-2021, the subject experienced vomiting. On 11-APR-2021, the subject experienced gastro-intestinal symptoms. On 11-APR-2021, the subject experienced headache. On 11-APR-2021, the subject experienced nausea. On 11-APR-2021, the subject experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from diarrhea, night sweats, chills, nausea, and fever on APR-2021, and vomiting on 11-APR-2021, was recovering from headache, muscle aches, fatigue, pain at injection site, and body pain, and the outcome of body temperature increased and gastro-intestinal symptoms was not reported. This report was non-serious.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Night sweats, Pain, Pyrexia, Vomiting
Clinical narrative: DIARRHEA; VOMITING; GASTRO-INTESTINAL SYMPTOMS; FATIGUE; HEADACHE; NAUSEA; MUSCLE ACHES; BODY PAIN; PAIN AT INJECTION SITE; BODY TEMPERATURE INCREASED; FEVER; NIGHT SWEATS; CHILLS; This spontaneous report received from a patient concerned a 56 year old female. The patient's weight was 176 pounds, and height was 63 inches. The patient's past medical history included covid-19 infection, low thyroid, and kidney disease, and concurrent conditions included bactrim allergy. The patient experienced drug allergy when treated with morphine, and hydrocodone bitartrate/paracetamol. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 10-APR-2021, the subject experienced body pain. On 10-APR-2021, the subject experienced night sweats. On 10-APR-2021, the subject experienced chills. On 10-APR-2021, the subject experienced muscle aches. On 10-APR-2021, the subject experienced pain at injection site. On 10-APR-2021, the subject experienced body temperature increased. On 10-APR-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 99.1 F. On 11-APR-2021, the subject experienced diarrhea. On 11-APR-2021, the subject experienced vomiting. On 11-APR-2021, the subject experienced gastro-intestinal symptoms. On 11-APR-2021, the subject experienced headache. On 11-APR-2021, the subject experienced nausea. On 11-APR-2021, the subject experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from diarrhea, night sweats, chills, nausea, and fever on APR-2021, and vomiting on 11-APR-2021, was recovering from headache, muscle aches, fatigue, pain at injection site, and body pain, and the outcome of body temperature increased and gastro-intestinal symptoms was not reported. This report was non-serious.
Age: 17.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Cardiac arrest, Chest pain, Death, Dyspnoea
Clinical narrative: From Post mortem report from Hospital: when on 4/10/21, she was in the process of self catheterization and began experiencing difficulty breathing and chest pain. Shortly after she collapsed and was not breathing. EMS arrived and found her apneic and  in pulseless electrical activity.  Resuscitation began and continued upon arrival to the ED.  Aside from a short period of returned pulses, she remained in PEA despite an estimated 45-50 minutes of resuscitation. She died at 11:20am on 4/10/21. - Directly from Pathology report  4.12.21